I have been looking for ADXS action lately. Good swings if you have stomach for it. Near-term target $1.20
Long term The company has cash into 2022. A few catalysts
ADXS-HOT: Off-the-shelf, tumor type-specific constructs ADXS-503 in NSCLC in Phase 1/2 study ADXS-504 in prostate cancer scheduled to enter the clinic in Q1 2021
Forthcoming Milestones
*ADXS-503: Phase 1/2 combination with KEYTRUDA--clinical and immune/biomarker data for KEYTRUDA failures as well as first-line patients ADXS-504: Clinical trial initiation; initial data readout ADXS-PSA: Announcement of next steps
The first patient dosed with HOT-Prostate by Q1 2021
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.